News and Trends 28 Jul 2023
FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment
The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44…
